Danish Biomonitor buys Neutekbio for €7 million
This article was originally published in Scrip
Executive Summary
Denmark's Biomonitor has bought Neutekbio, an Irish company focused on reporter gene technology, for more than €7 million. Neutekbio's largest stakeholder Growcorp, Ireland's first private company with an investment fund targeted specifically at the bioscience sector, will hold a 6% stake in Biomonitor. Galway-based Neutekbio has developed iLite, cell-based assays and kits that measure biological activity of cytokines such as interferons and neutralising antibodies to IFN and TNF-alpha antagonists. These assays are essential for monitoring drug profiles and the potential of immunogenicity of biopharmaceutical drugs throughout the entire development and postmarketing testing. Arsalan Kharazmi, Biomonitor CEO, said the acquisition would make Biomonitor the leading theranostic company. The Danish company, which has developed assays to monitor antibodies to several anti-inflammatory drugs, will continue the R&D and manufacturing operations in Ireland. Sunstone Capital, a Nordic early-stage venture capital investor, will provide funding for the acquisition. Growcorp has invested €3 million in Neutekbio since 2003, while Enterprise Equity and western Development Corporation contributed €1 million each.
You may also be interested in...
Innovation not M&A to drive Bayer growth in LatAm
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
2010 Scrip 100 - Is Anvisa a friend of innovators?
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan raises $1.5 billion
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.